What question did this study set out to answer?

This correction addresses errors in the reporting of NfL data and neurodegeneration outcomes in SMA.

April 26, 2026Open Access

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Key Points

This correction addresses errors in the reporting of NfL data and neurodegeneration outcomes in SMA.
Phase 3 randomized trial evaluating high-dose nusinersen in spinal muscular atrophy.
Comparison includes data from the ENDEAR matched sham group.
Corrected the reduction in neurodegeneration from 30% to 32% compared to the sham group; p=0.0075.
Adjusted nominally significant p-value for later-onset SMA neurodegeneration from 0.0495 to 0.0047.

Abstract

In the version of the article initially published, there were errors in the NfL data in Fig. 2, Table 2 and Extended Data Fig. 4. The original figures and table are available for comparison in the Supplementary information accompanying this amendment.In the Results, in the "Part B cohort with infantile-onset SMA: neurodegeneration" section, the text "compared with the ENDEAR matched sham group (30% reduction)" has been corrected to "compared with the ENDEAR matched sham group (32% reduction)", and "nominally significant P = 0.0050" has been corrected to "nominally significant P = 0.0075".In the "Part B cohort with later-onset SMA: neurodegeneration" section, the text "nominally significant P = 0.0495" has been corrected to "nominally significant P = 0.0047".

KI fragen

Bookmark

View Full Paper

Cite This Study

Finkel et al. (Thu,) studied this question.

synapsesocial.com/papers/69edab424a46254e215b35db https://doi.org/https://doi.org/10.1038/s41591-026-04415-5

KI fragen

Bookmark

View Full Paper